K-group, Beta, Inc., A Wholly Owned Subsidiary Of Zentalis Pharmaceuticals, Inc

This study tested an experimental drug called ZN-c3 in 92 women with a rare and aggressive type of uterine cancer that had come back or not gone away. The goal was to see if the drug could shrink tumors and to check for side effects. Participants had already tried other treatment…

This study tested a new drug called azenosertib (ZN-c3) combined with the chemotherapy gemcitabine in people aged 12 and older whose osteosarcoma (a type of bone cancer) had returned or stopped responding to treatment. The goal was to see if the combination is safe and can slow o…

This study tested an experimental drug called ZN-c3, given alone or with another drug (niraparib), in 117 people with ovarian cancer that stopped responding to platinum-based chemotherapy. The goal was to find safe doses and see if the treatment could shrink tumors or slow the di…

This early-stage study tested a new drug, ZN-c3 (Azenosertib), in 274 adults with solid tumors. The main goals were to find a safe dose and see if the drug can shrink tumors. The study is now complete, and results will help decide if further testing is needed.